The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis
Open accessThe DOI matches its Crossref record; 69 of the 70 references it cites were found in a registry or an index.
Abstract
CXCL13 is a key B cell chemoattractant and marker of disease activity in patients with SLE; however, the mechanism of its induction has not been identified yet. Here, we have shown that the proteoglycan biglycan triggers CXCL13 expression via TLR2/4 in macrophages and dendritic cells. In vivo, levels of biglycan were markedly elevated in the plasma and kidneys of human SLE patients and lupus-prone (MRL/lpr) mice. Overexpression of soluble biglycan in MRL/lpr mice raised plasma and renal levels of CXCL13 and caused accumulation of B cells with an enhanced B1/B cell ratio in the kidney, worsening of organ damage, and albuminuria. Importantly, biglycan also triggered CXCL13 expression and B cell infiltration in the healthy kidney. Conversely, biglycan deficiency improved systemic and renal outcome in lupus-prone mice, with lower levels of autoantibodies, less enlargement of the spleen and lymph nodes, and reduction in renal damage and albuminuria. This correlated with a marked decline in circulating and renal CXCL13 and a reduction in the number of B cells in the kidney. Collectively, our results describe what we believe to be a novel mechanism for the regulation of CXCL13 by biglycan, a host-derived ligand for TLR2/4. Blocking biglycan-TLR2/4 interactions might be a promising strategy for the management of SLE and other B cell-mediated inflammatory disease entities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Innate immune cells also recognize glycans released from tissue damage in vertebrates such as hyaluronan fragments (467, 914 -915) and some matrix proteoglycans (956 -957) as danger-associated molecular patterns (DAMPs) or ' alarmins ' , triggering responses similar to those generated by exogenous PAMPs”
From Biological roles of glycans (2017) · cites this paper as [956]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Lawrence, R. C., Felson, D. T., Helmick, C. G., Arnold, L. M., Choi, H., Deyo, R. A., Gabriel, S., Hirsch, R., Hochberg, M. C., Hunder, G. G., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23176 · Cited by 5,499
Derivation of the sledai. A disease activity index for lupus patients
Bombardier, C., Gladman, D. D., Urowitz, M. B., Caron, D., Chang, C. H., Austin, A., Bell, A., Bloch, D. A., Corey, P. N., Decker, J. L., et al. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780350606 · Cited by 4,570
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I
Helmick, C. G., Felson, D. T., Lawrence, R. C., Gabriel, S., Hirsch, R., Kwoh, C. K., Liang, M. H., Kremers, H. M., Mayes, M. D., Merkel, P. A., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23177 · Cited by 2,058
Rahman, A., & Isenberg, D. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmra071297 · Cited by 1,632
Förster, R., Mattis, A. E., Kremmer, E., Wolf, E., Brem, G., & Lipp, M. (1996) · Cell · doi:10.1016/s0092-8674(00)81798-5 · Cited by 1,129
Rahman, M. U. (2008) · Essentials of Physical Medicine and Rehabilitation · doi:10.1016/b978-1-4160-4007-1.50153-x · Cited by 1,019
Martin, F., Oliver, A. M., & Kearney, J. F. (2001) · Immunity · doi:10.1016/s1074-7613(01)00129-7 · Cited by 985
Schaefer, L., Babelova, A., Kiss, E., Hausser, H.-J., Baliova, M., Krzyzankova, M., Marsche, G., Young, M. F., Mihalik, D., Götte, M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23755 · Cited by 850
Self-citationTLR4 activation mediates kidney ischemia/reperfusion injury
Wu, H., Chen, G., Wyburn, K. R., Yin, J., Bertolino, P., Eris, J. M., Alexander, S. I., Sharland, A. F., & Chadban, S. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31008 · Cited by 836
Cited by
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“(956, 957) as DAMPs or "alarmins", triggering responses similar to those generated by exogenous PAMPs”
BackgroundComplexity of Danger: The Diverse Nature of Damage-associated Molecular Patterns
Schaefer, L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.619304 · Cited by 622
Self-citationZhu, S., Pan, W., Song, X., Liu, Y., Shao, X., Tang, Y., Liang, D., He, D., Wang, H., Liu, W., et al. (2012) · Nature Medicine · doi:10.1038/nm.2815 · Cited by 396
TLR2 and TLR4 in Autoimmune Diseases: a Comprehensive Review
Liu, Y., Yin, H., Zhao, M., & Lu, Q. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-013-8402-y · Cited by 365
“Conversely, activation of TLR2/4 by proteoglycan biglycanin MRL/lpr mice can trigger CXCL13 expression and cause accumulation of B cells with an enhanced B1/B cell ratio in the kidney [80].”
BackgroundMerline, R., Moreth, K., Beckmann, J., Nastase, M. V., Zeng-Brouwers, J., Tralhão, J. G., Lemarchand, P., Pfeilschifter, J., Schaefer, R. M., Iozzo, R. V., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2001868 · Cited by 333
“Like decorin, the small leucine-rich proteoglycan biglycan also signals through both TLR2 and TLR4 (29), thereby regulating pathogen-mediated and sterile inflammation (29, 35) and mediating both innate and adaptive immune responses (36).”
BackgroundMethodInfluentialSelf-citationAnders, H.-J., & Schaefer, L. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014010117 · Cited by 330
Self-citationTargeting renal fibrosis: Mechanisms and drug delivery systems
Nastase, M. V., Zeng-Brouwers, J., Wygrecka, M., & Schaefer, L. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.12.019 · Cited by 302
Self-citationNeill, T., Schaefer, L., & Iozzo, R. V. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.04.029 · Cited by 304
Self-citationEscape from X Inactivation Varies in Mouse Tissues
Berletch, J. B., Ma, W., Yang, F., Shendure, J., Noble, W. S., Disteche, C. M., & Deng, X. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1005079 · Cited by 301
“Interestingly, of the five novel spleen-specific escape genes we identified, as many as three, Vsig4, Cfp, and Bgn, have been implicated in autoimmune disorders both in mouse and human [36,38,39].”
BackgroundBiological interplay between proteoglycans and their innate immune receptors in inflammation
Frey, H., Schroeder, N., Manon‐Jensen, T., Iozzo, R. V., & Schaefer, L. (2013) · The FEBS Journal · doi:10.1111/febs.12145 · Cited by 274
Self-citationVarki, A. (2011) · Glycobiology · doi:10.1093/glycob/cwr087 · Cited by 263
“The innate immune system also recognizes “danger-associated molecular patterns” (DAMPs; Matzinger 2002; Chen and Nunez 2010), molecules released during tissue damage, such as heat-shock proteins, high mobility group box 1 (Lotze and Tracey 2005), hyaluronan (HA) fragments (Taylor and Gallo 2006), glycosaminoglycan (GA…”
BackgroundBiglycan: A Multivalent Proteoglycan Providing Structure and Signals
Nastase, M. V., Young, M. F., & Schaefer, L. (2012) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155412456380 · Cited by 238
“Research over the past few years has provided strong evidence that biglycan in its soluble form acts as danger signal bridging the innate and adaptive immune systems (Schaefer et al. 2005; Babelova et al. 2009; Moreth et al. 2010; Popovic et al. 2011; Schaefer and Iozzo 2012).”
BackgroundInfluentialSelf-citationAn Introduction to Proteoglycans and Their Localization
Couchman, J. R., & Pataki, C. A. (2012) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155412464638 · Cited by 232
“Recent work, summarized in this volume (Nastase et al. 2012), points to yet another vital function for members of the SLRP family, notably biglycan and decorin, and that is regulation of the innate immune system (Moreth et al. 2010; Merline et al. 2011).”
BackgroundLupus nephritis: A critical review
Borchers, A. T., Leibushor, N., Naguwa, S. M., Cheema, G. S., Shoenfeld, Y., & Gershwin, M. E. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.08.018 · Cited by 229
Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment
Zhang, W., Ge, Y., Cheng, Q., Zhang, Q., Fang, L., & Zheng, J. (2018) · Oncotarget · doi:10.18632/oncotarget.23869 · Cited by 204
“Oncotarget5483www.impactjournals.com/oncotarget Oncotarget5484www.impactjournals.com/oncotarget Furthermore, by down-regulating the bioactivity of TGF-β1, DCN decreases the abundance of oncogenic microRNA (miR-21), a transcriptional inhibitor of a tumour suppressor named programmed cell death protein 4 (PDCD4), in a T…”
BackgroundSmall leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation
Moreth, K., Iozzo, R. V., & Schaefer, L. (2012) · Cell Cycle · doi:10.4161/cc.20316 · Cited by 158
“In patients with lupus nephritis and in lupus-prone mice, the presence of circulating biglycan has been described.(8) This is of particular relevance, because only soluble biglycan is capable of acting as a proinflammatory signaling molecule.”
BackgroundSelf-citationInsights into the key roles of proteoglycans in breast cancer biology and translational medicine
Theocharis, A. D., Skandalis, S. S., Neill, T., Multhaupt, H. A. B., Hubo, M., Frey, H., Gopal, S., Gomes, A. M., Afratis, N. A., Lim, H. C., et al. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.03.006 · Cited by 182
Self-citationProteoglycan neofunctions: regulation of inflammation and autophagy in cancer biology
Schaefer, L., Tredup, C., Gubbiotti, M. A., & Iozzo, R. V. (2016) · FEBS Journal · doi:10.1111/febs.13963 · Cited by 168
“C motif) ligand (CCL)2, chemokine (C-X-C motif) ligand (CXCL)1, CXCL-2, CXCL13, and CCL5 [83,84,86,87] (Fig.”
Self-citationImmunomodulatory Role of the Extracellular Matrix Within the Liver Disease Microenvironment
McQuitty, C. E., Williams, R., Chokshi, S., & Urbani, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.574276 · Cited by 146
Moreth, K., Frey, H., Hubo, M., Zeng-Brouwers, J., Nastase, M.-V., Hsieh, L. T.-H., Haceni, R., Pfeilschifter, J., Iozzo, R. V., & Schaefer, L. (2014) · Matrix Biology · doi:10.1016/j.matbio.2014.01.010 · Cited by 142
Self-citationThe interplay of extracellular matrix and microbiome in urothelial bladder cancer
Alfano, M., Canducci, F., Nebuloni, M., Clementi, M., Montorsi, F., & Salonia, A. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2015.292 · Cited by 134
Decoding the Matrix: Instructive Roles of Proteoglycan Receptors
Neill, T., Schaefer, L., & Iozzo, R. V. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00653 · Cited by 140
Self-citationRole of the CXCL13/CXCR5 Axis in Autoimmune Diseases
Pan, Z., Zhu, T., Liu, Y., & Zhang, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850998 · Cited by 155
The pathogenesis, diagnosis and treatment of lupus nephritis
Schwartz, N., Goilav, B., & Putterman, C. (2014) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000089 · Cited by 131
Resident fibroblasts in the kidney: a major driver of fibrosis and inflammation
Sato, Y., & Yanagita, M. (2017) · Inflammation and Regeneration · doi:10.1186/s41232-017-0048-3 · Cited by 124
“Though monocyte lineage cells have also been reported as CXCL13-producing cells in murine lupus models in the kidney [54, 55], the expression of CXCL13 in fibroblasts was not examined in these studies, and the relative contribution of hematopoietic cells and non-hematopoietic cells to overall CXCL13 expression in the…”
Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments
Merz, F., Gaunitz, F., Dehghani, F., Renner, C., Meixensberger, J., Gutenberg, A., Giese, A., Schopow, K., Hellwig, C., Schäfer, M., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not003 · Cited by 123
Kramer, J. M., Klimatcheva, E., & Rothstein, T. L. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0113036 · Cited by 122
Poluzzi, C., Nastase, M.-V., Zeng-Brouwers, J., Roedig, H., Hsieh, L. T.-H., Michaelis, J. B., Buhl, E. M., Rezende, F., Manavski, Y., Bleich, A., et al. (2019) · Kidney International · doi:10.1016/j.kint.2018.10.037 · Cited by 119
Self-citationSelective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis
Rankin, A. L., Seth, N., Keegan, S., Andreyeva, T., Cook, T. A., Edmonds, J., Mathialagan, N., Benson, M. J., Syed, J., Zhan, Y., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301553 · Cited by 113
A core matrisome gene signature predicts cancer outcome
Yuzhalin, A. E., Urbonas, T., Silva, M. A., Muschel, R. J., & Gordon-Weeks, A. N. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.458 · Cited by 113
“BGN, for example, interacts with toll-like receptors on the surface of macrophages to promote the synthesis of TNFa and CCL2 (Schaefer et al, 2005; Moreth et al, 2010); both cytokines important for cancer (Balkwill, 2006; Lim et al, 2016).”
BackgroundGerlach, M. M., Merz, F., Wichmann, G., Kubick, C., Wittekind, C., Lordick, F., Dietz, A., & Bechmann, I. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.700 · Cited by 129
“For example, ECM epitopes provide important differentiation cues, for example, by signalling via Toll-like receptors (Schaefer et al, 2005; Senner et al, 2008; Moreth et al, 2010; Merline et al, 2011) and integrins (Abdollahi et al, 2005; Alghisi et al, 2009).”
BackgroundLitsiou, E., Semitekolou, M., Galani, I. E., Morianos, I., Tsoutsa, A., Kara, P., Rontogianni, D. P., Bellenis, I. P., Konstantinou, M., Potaris, Κ., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201208-1543oc · Cited by 108
“TLR activation in B cells by respiratory pathogens, endogenous mediators, or extracellular matrix degradation products may increase B-cell LT, which in turn acts on the same or other B cells to induce expression of the B-cell chemoattractant CXCL13 (43).”
Pimenta, E., & Barnes, B. (2014) · Cancers · doi:10.3390/cancers6020969 · Cited by 99
The Role of Decorin and Biglycan Signaling in Tumorigenesis
Diehl, V., Huber, L. S., Trebicka, J., Wygrecka, M., Iozzo, R. V., & Schaefer, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.801801 · Cited by 105
Self-citationFava, R. A., Kennedy, S., Wood, S. G., Bolstad, A. I., Bienkowska, J. R., Papandile, A., Kelly, J. A., Mavragani, C. P., Gatumu, M. K., Skarstein, K., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3507 · Cited by 93
“Yet another possibility is the induction of CXCL13 expression in macrophages by biglycan, a byproduct of degradation of the extra-cellular matrix known to occur in diseased lacrimal glands [46,60].”
BackgroundAge-dependent hepatic lymphoid organization directs successful immunity to hepatitis B
Publicover, J., Gaggar, A., Nishimura, S. L., Horn, C. M. V., Goodsell, A., Muench, M. O., Reinhardt, R. L., van Rooijen, N., Wakil, A. E., Peters, M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68182 · Cited by 94
Zeng-Brouwers, J., Beckmann, J., Nastase, M.-V., Iozzo, R. V., & Schaefer, L. (2013) · Matrix Biology · doi:10.1016/j.matbio.2013.12.003 · Cited by 95
“In agreement with these experimental data, increased biglycan expression occurs in a number of pathogenic and sterile inflammatory conditions (WestergrenThorsson et al., 1993; Schaefer et al., 2002; de Kluijver et al., 2005; Derbali et al., 2010; Moreth et al., 2010; Popovic et al., 2011; Adapala et al., 2012).”
InfluentialSelf-citationThe Th17/IL-17 Axis and Kidney Diseases, With Focus on Lupus Nephritis
Paquissi, F. C., & Abensur, H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.654912 · Cited by 101
A brief elevation of serum amyloid A is sufficient to increase atherosclerosis
Thompson, J. C., Jayne, C., Thompson, J., Wilson, P. G., Yoder, M. H., Webb, N. R., & Tannock, L. R. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m054015 · Cited by 95
“the recruitment of more monocyte/macrophages to sites of tissue injury (31) (32).”
BackgroundBiglycan is a new high-affinity ligand for CD14 in macrophages
Roedig, H., Nastase, M. V., Frey, H., Moreth, K., Zeng-Brouwers, J., Poluzzi, C., Hsieh, L. T.-H., Brandts, C., Fulda, S., Wygrecka, M., et al. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.05.006 · Cited by 98
Self-citationSmall leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation
Schaefer, L., & Iozzo, R. V. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2011.12.002 · Cited by 85
“Notably, biglycan attracts B cells to chronically inflamed nonlymphoid organs and promotes the development of tertiary lymphoid tissue and acceleration of disease [9].”
Self-citationSoluble biglycan as a biomarker of inflammatory renal diseases
Hsieh, L. T.-H., Nastase, M.-V., Zeng-Brouwers, J., Iozzo, R. V., & Schaefer, L. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.07.020 · Cited by 94
“In a UUO model, biglycan overexpression in epithelial cells of distal tubules appears before macrophage infiltration (Leemans et al., 2009, Moreth et al., 2010, Schaefer et al., 2002, Schaefer, 2011).”
BackgroundInfluentialSelf-citationInnate immunity in Sjögren's syndrome
Kiripolsky, J., McCabe, L. G., & Kramer, J. M. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.04.003 · Cited by 85
“Specifically, the ECM molecules biglycan and tenascin-c are implicated in SLE and RA pathogenesis, respectively [16, 18].”
BackgroundAdvances in Toll-like receptor biology: Modes of activation by diverse stimuli
Bryant, C. E., Gay, N. J., Heymans, S. R. B., Sacre, S. M., Schaefer, L., & Midwood, K. S. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1033511 · Cited by 97
“Moreover, we found that soluble biglycan was elevated in plasma and kidney of patients with systemic lupus erythematosus (SLE) as well as in lupus prone mice where it correlates with circulating CXCL13, albuminuria and organ damage (Moreth et al., 2010).”
BackgroundMethodInfluentialSelf-citationSmall Leucine-Rich Proteoglycans in Kidney Disease
Schaefer, L. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010050570 · Cited by 86
Self-citationInflammation in Right Ventricular Failure: Does It Matter?
Dewachter, L., & Dewachter, C. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01056 · Cited by 77
“, 1985) and inflammation regulation (Iozzo and Schaefer, 2010; Moreth et al., 2010).”
The small leucine‐rich repeat proteoglycans in tissue repair and atherosclerosis
Hultgårdh‐Nilsson, A., Borén, J., & Chakravarti, S. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12400 · Cited by 76
Immunopathology of lupus nephritis
Anders, H., & Fogo, A. B. (2014) · Seminars in Immunopathology · doi:10.1007/s00281-013-0413-5 · Cited by 76
Lee, W., Ko, S. Y., Akasaka, H., Weigert, M., Lengyel, E. R., & Naora, H. (2025) · Cancer Cell · doi:10.1016/j.ccell.2024.12.004 · Cited by 85
Chemokines and Chemokine Receptors in the Development of Lupus Nephritis
Liao, X., Pirapakaran, T., & Luo, X. (2016) · Mediators of Inflammation · doi:10.1155/2016/6012715 · Cited by 78
Roedig, H., Nastase, M. V., Wygrecka, M., & Schaefer, L. (2019) · FEBS Journal · doi:10.1111/febs.14791 · Cited by 75
Self-citationInfectious diseases, autoantibodies, and autoimmunity
Johnson, D., & Jiang, W. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102962 · Cited by 83
Guo, D., Zhang, W., Yang, H., Bi, J., Xie, Y., Cheng, B., Wang, Y., & Chen, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225716 · Cited by 70
Key roles for the small leucine-rich proteoglycans in renal and pulmonary pathophysiology
Nastase, M. V., Iozzo, R. V., & Schaefer, L. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.01.035 · Cited by 76
Self-citationSoluble biglycan: a potential mediator of cartilage degradation in osteoarthritis
Barreto, G., Soininen, A., Ylinen, P., Sandelin, J., Konttinen, Y. T., Nordström, D., & Eklund, K. K. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0902-0 · Cited by 70
“For example, sBGN, the size of which is approximately 95 kDa, has been shown trigger TLR4/TLR2 signalling in human aortic valve and in acute ischemic kidney, as well as to activate the NLRP3 inflammasome in macrophages [15–17].”
BackgroundSchiffer, L. E., Worthmann, K., Haller, H. G., & Schiffer, M. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12439 · Cited by 67
Brown, S. J., Melrose, J., Caterson, B., Roughley, P. J., Eisenstein, S. M., & Roberts, S. (2012) · European Spine Journal · doi:10.1007/s00586-012-2179-1 · Cited by 61
“When the complex is activated it can lead to many other effects including caspase activation and generation of the cytokines, TNFa and IL-1b [20].”
BackgroundBiglycan, a novel trigger of Th1 and Th17 cell recruitment into the kidney
Nastase, M. V., Zeng-Brouwers, J., Beckmann, J., Tredup, C., Christen, U., Radeke, H. H., Wygrecka, M., & Schaefer, L. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.12.002 · Cited by 60
Self-citationDanger matrix molecules orchestrate CD14/CD44 signaling in cancer development
Roedig, H., Damiescu, R., Zeng-Brouwers, J., Kutija, I., Trebicka, J., Wygrecka, M., & Schaefer, L. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.026 · Cited by 68
Self-citationProteoglycan signaling in tumor angiogenesis and endothelial cell autophagy
Gubbiotti, M. A., Buraschi, S., Kapoor, A., & Iozzo, R. V. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.05.003 · Cited by 63
Current and Emerging Evidence for Toll-Like Receptor Activation in Sjögren’s Syndrome
Kiripolsky, J., & Kramer, J. M. (2018) · Journal of Immunology Research · doi:10.1155/2018/1246818 · Cited by 62
Li, C., Maishi, N., Annan, D. A., Young, M. F., Morimoto, H., Morimoto, M., Nam, J.-M., Hida, Y., & Hida, K. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01423-w · Cited by 65
“Biglycan is proteolytically cleaved from the ECM upon tissue stress or injury in a soluble form, thereby acting as a damage-associated molecular pattern (DAMP) protein [19].”
BackgroundSelf-citationAppunni, S., Rubens, M., Ramamoorthy, V., Anand, V., Khandelwal, M., & Sharma, A. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04216-z · Cited by 57
Bimodal role of NADPH oxidases in the regulation of biglycan-triggered IL-1β synthesis
Hsieh, L. T.-H., Frey, H., Nastase, M.-V., Tredup, C., Hoffmann, A., Poluzzi, C., Zeng-Brouwers, J., Manon‐Jensen, T., Schröder, K., Brandes, R. P., et al. (2015) · Matrix Biology · doi:10.1016/j.matbio.2015.12.005 · Cited by 59
“In macrophages, biglycan-evoked IL-1β production is associated with ROS-dependent NLRP3 inflammasome activation [15,19].”
BackgroundSelf-citationSyrett, C. M., Sierra, I., Beethem, Z. T., Dubin, A. H., & Anguera, M. C. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102357 · Cited by 56
Beetz, N., Rommel, C., Schnick, T., Neumann, E., Lother, A., Ordonez, E. B. M., Zeeb, M., Preißl, S., Gilsbach, R., Melchior‐Becker, A., et al. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.10.011 · Cited by 57
Self-citationProteoglycans and Immunobiology of Cancer—Therapeutic Implications
Tzanakakis, G. N., Neagu, M. T., Tsatsakis, A. M., & Nikitovic, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00875 · Cited by 60
“Furthermore, TLR2/4 induced ROS generation by biglycan (56) stimulates macrophages and dendritic cells to express chemokine (C-X-C) ligand 13 (CXCL13), the major chemoattractant for B and B1 lymphocytes (56).”
BackgroundUrbonaviciute, V., Starke, C., Pirschel, W., Pohle, S., Frey, S., Daniel, C., Amann, K., Schett, G. A., i, M. H., & Voll, R. E. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37914 · Cited by 56
Maiti, G., Frikeche, J., Lam, C. Y.-M., Biswas, A., Shinde, V., Samanovic, M., Kagan, J. C., Mulligan, M. J., & Chakravarti, S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2100999118 · Cited by 53
“Bgn, a Lum-like SLRP, was found to be associated with overexpression and overactive TLR2 and TLR4 signals in autoimmune lupus nephritis, but TLR9 signals were not explored in that model either (56).”
BackgroundMortensen, J. H., Manon‐Jensen, T., Jensen, M. D., Hägglund, P., Klinge, L. G., Kjeldsen, J., Krag, A. A., Karsdal, M. A., & Bay‐Jensen, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185855 · Cited by 52
Kiripolsky, J., Romano, R., Kasperek, E. M., Yu, G., & Kramer, J. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02963 · Cited by 55
“As tissue breakdown continues, Dcn levels may become elevated systemically, as is observed for the related DAMP biglycan in SLE patients (44), and this may be a mechanism contributing to the systemic disease manifestations observed in pSS.”
BackgroundResultRodgers, D. T., Pineda, M. A., McGrath, M. A., Al‐Riyami, L., Harnett, W., & Harnett, M. M. (2014) · Immunology · doi:10.1111/imm.12208 · Cited by 48
Zeng-Brouwers, J., Pandey, S., Trebicka, J., Wygrecka, M., & Schaefer, L. (2020) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155420930303 · Cited by 48
Self-citationWæhre, A., Vistnes, M., Sjaastad, I., Nygård, S., Husberg, C., Lunde, I. G., Aukrust, P., Yndestad, A., Vinge, L. E., Behmen, D., et al. (2012) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01350.2011 · Cited by 48
“directly regulate inflammatory processes (13, 18).”
Cohen, K. W., Dugast, A., Alter, G., McElrath, M. J., & Stamatatos, L. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1400952 · Cited by 46
“upon stimulation of the TLR 2 and 4 pathways (17, 29, 30), and be-”
BackgroundSmall leucine-rich repeat proteoglycans in corneal inflammation and wound healing
Frikeche, J., Maiti, G., & Chakravarti, S. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2016.08.015 · Cited by 44
“Biglycan (Moreth et al., 2010; Schaefer et al., 2005) and decorin (Koninger et al.”
BackgroundAppunni, S., Anand, V., Khandelwal, M., Seth, A., Mathur, S. R., & Sharma, A. (2017) · Tumor Biology · doi:10.1177/1010428317699112 · Cited by 47
Biglycan and atherosclerosis: Lessons from high cardiovascular risk conditions
Scuruchi, M., Potì, F., Rodríguez‐Carrio, J., Campo, G. M., & Mandraffino, G. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.158545 · Cited by 47
“Furthermore, through TLR2 and -4 signaling, sBGN mediates the synthesis of various chemokines for neutrophils and macrophages, such as MIP-1α, MIP-2, MCP-1 and RANTES, mediating ex novo or amplifying inflammation [82, 101].”
BackgroundSmall Leucine-Rich Proteoglycans in Renal Inflammation: Two Sides of the Coin
Nastase, M. V., Janicova, A., Roedig, H., Hsieh, L. T.-H., Wygrecka, M., & Schaefer, L. (2018) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155417738752 · Cited by 46
“various other chemokines such as CCL2, CCL3, CCL5, CXCL13 led to enhanced recruitment of macrophages and T and B lymphocytes into the kidney, causing aggravation of organ damage.(16) By contrast, biglycan deficiency ameliorated the progression of LN.”
BackgroundSelf-citationSTINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development
Filderman, J. N., Appleman, M., Chelvanambi, M., Taylor, J. L., & Storkus, W. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690105 · Cited by 45
Jonas, A., Thiem, S., Kuhlmann, T., Wagener, R., Aszódi, A., Nowell, C. J., Hagemeier, K., Laverick, L., Perreau, V. M., Jokubaitis, V., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71385 · Cited by 42
Decorin in the Tumor Microenvironment
Baghy, K., Reszegi, A., Tátrai, P., & Kovalszky, I. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-48457-6_2 · Cited by 42
The basement membrane in the cross-roads between the lung and kidney
Jandl, K., Mutgan, A. C., Eller, K., Schaefer, L., & Kwapiszewska, G. (2021) · Matrix Biology · doi:10.1016/j.matbio.2021.11.003 · Cited by 41
Self-citationXia, M., Yu, R., & Chen, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.809325 · Cited by 48
Song, R., Ao, L., Zhao, K.-S., Zheng, D., Venardos, N., Fullerton, D. A., & Meng, X. (2014) · Inflammation Research · doi:10.1007/s00011-014-0743-3 · Cited by 37
“toneal macrophages, biglycan induces the production of proinflammatory cytokines, such as TNF-a, pro–IL-1b, MIP-2, MIP-1a, MCP-1, CXCL13, and RANTES [11, 14].”
BackgroundHsieh, L. T.-H., Nastase, M.-V., Roedig, H., Zeng-Brouwers, J., Poluzzi, C., Schwalm, S. A., Fork, C., Tredup, C., Brandes, R. P., Wygrecka, M., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030595 · Cited by 37
“By contrast, it is well known that biglycan acts as a trigger of TNFα and IL1β protein in macrophages, requiring at least two hours of stimulation before the cytokines can be detected [5,9,37].”
BackgroundMethodInfluentialSelf-citationLi, C., Wu, F., Mao, J., Wang, Y., Zhu, J., Hong, K., Xie, H., Zhou, X., Tian, J., & Wen, C. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03834-w · Cited by 44
“The elevated B1/B ratio in the kidney of MRL/lpr mice exacerbates the progression of LN [49].”
BackgroundSignaling at the Crossroads: Matrix-Derived Proteoglycan and Reactive Oxygen Species Signaling
Nastase, M.-V., Janicova, A., Wygrecka, M., & Schaefer, L. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7165 · Cited by 37
“C motif) ligand (CCL)2, chemokine (C-X-C motif) ligand (CXCL)1, CXCL-2, CXCL13, and CCL5 (6, 113, 115, 154).”
InfluentialSelf-citationEffect of mycophenolate and rapamycin on renal fibrosis in lupus nephritis
Zhang, C., Chan, C. C. Y., Cheung, K. F., Chau, M. K. M., Yap, D. Y. H., Ma, M. K. M., Chan, K. W., Yung, S., & Chan, T. M. (2019) · Clinical Science · doi:10.1042/cs20190536 · Cited by 35
Myd88 is required for disease development in a primary Sjögren's syndrome mouse model
Kiripolsky, J., McCabe, L. G., Gaile, D. P., & Kramer, J. M. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a0717-311r · Cited by 33
Proteoglycans in the Pathogenesis of Hormone-Dependent Cancers: Mediators and Effectors
Tzanakakis, G. N., Giatagana, E.-M., Николаевич, К. А., Berdiaki, A., Tsatsakis, A. M., Neagu, M. T., & Nikitovic, D. (2020) · Cancers · doi:10.3390/cancers12092401 · Cited by 33
“These authors produced a CCL2 mutant protein fused to human serum albumin (dnCCL2–HSA chimera) which exhibits a high affinity to GAG chains.”
BackgroundInfluentialKelsh, R., & McKeown‐Longo, P. J. (2013) · PubMed · Cited by 40
Toll-Like Receptor 3 Mediates Aortic Stenosis Through a Conserved Mechanism of Calcification
Gollmann‐Tepeköylü, C., Graber, M., Hirsch, J., Mair, S., Naschberger, A., Pölzl, L., Nägele, F., Kirchmair, E., Degenhart, G., Demetz, E., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.063481 · Cited by 37
Halari, C. D., Zheng, M., & Lala, P. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910584 · Cited by 34
Xie, Y., Peng, J., Pang, J., Guo, K., Zhang, L., Yin, S., Zhou, J., Gu, L., Tu, T., Mu, Q., et al. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14926 · Cited by 34
“(b–d) n = 3 independent cell culture preparations) in renal ischemia–reperfusion injury mice and lupus-prone mice, and this histopathology was abolished in Tlr4−/− mice (Moreth et al., 2010, 2014).”
BackgroundBiglycan: A regulator of hepatorenal inflammation and autophagy
McCoy, M. S., Diehl, V., Trebicka, J., Wygrecka, M., & Schaefer, L. (2021) · Matrix Biology · doi:10.1016/j.matbio.2021.06.001 · Cited by 35
Self-citationDistinct effects of mycophenolate mofetil and cyclophosphamide on renal fibrosis in NZBWF1/J mice
Yung, S., Zhang, Q., Chau, M. K. M., & Chan, T. M. (2015) · Autoimmunity · doi:10.3109/08916934.2015.1054027 · Cited by 35
“interstitium and blood vessels were graded 0–3 (for normal, mild, moderate and severe) and expressed as mean glomerular, tubulo-interstitial and blood vessel lesion scores for each group [21].”
BackgroundMethodFuchs, S., Hsieh, L. T.-H., Saarberg, W., Erdelmeier, C. A. J., Wichelhaus, T. A., Schaefer, L., Koch, E., & Fürst, R. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12493 · Cited by 36
“Serial sections (4 lm) of paraffin-embedded samples were processed for immunohistochemical studies using rat anti-mouse F4/80 antiserum (macrophage marker; AbD Serotec, Puchheim, Germany) and horseradish peroxidase/3,30-diaminobenzidine techniques [25, 26].”
MethodSelf-citationThe Role of B1 Cells in Systemic Lupus Erythematosus
She, Z., Li, C., Wu, F., Mao, J., Xie, M., Hun, M., Abdirahman, A. S., Luo, S., Wan, W., Tian, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.814857 · Cited by 36
“Through the proteoglycan biglycan-toll-like receptor (TLR)2/4 pathway, CXCL13 levels can be increased in the kidney, which aggregates B1 cells that interact with other cells and damage the glomerular and tubular interstitium (55), whereas, through TLRs, the aggregation of B1 cells in the spleen can be regulated (52).”
BackgroundCXCL13 blockade attenuates lupus nephritis of MRL/lpr mice
Wu, X., Guo, J., Ding, R., Lv, B., & Bi, L. (2015) · Acta Histochemica · doi:10.1016/j.acthis.2015.09.001 · Cited by 32
Metadata
- Authors
- Moreth, K., Brodbeck, R., Babelova, A., Gretz, N., Spieker, T., Zeng-Brouwers, J., Pfeilschifter, J., Young, M. F., Schaefer, R. M., & Schaefer, L.
- Affiliations
- Goethe University Frankfurt (DE)
- Heidelberg University (DE)
- University of Münster (DE)
- National Institutes of Health (US)
- Corresponding author
- Schaefer, Liliana
- Venue
- Journal of Clinical Investigation
- Published
- 2010-12-01
- Volume
- 120
- Issue
- 12
- Pages
- 4251-4272
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2993585
- OpenAlex
- W1968712129
- Cited by
- 207
- References
- 70
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 10 · 2023: 11 · 2022: 20 · 2021: 22 · 2020: 13 · 2019: 15 · 2018: 8 · 2017: 12 · 2016: 8 · 2015: 18 · 2014: 15 · 2013: 14 · 2012: 18
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (GRK1172, Project A7, SFB 815, project A5)
- Else Kröner-Fresenius-Stiftung
- Goethe-Universität Frankfurt am Main
- National Institutes of Health (SFB 815)
- National Institute of Dental and Craniofacial Research
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Keywords
- biglycan, CXCL13, systemic lupus erythematosus, lupus nephritis, TLR2/4 signaling, proteoglycans, macrophages, dendritic cells, MRL/lpr mice, albuminuria, autoantibodies
- MeSH terms
- Adolescent, Adult, Animals, B-Lymphocytes, Diabetic Nephropathies, Female, Graft Rejection, Humans, Kidney, Lupus Erythematosus, Systemic, Lupus Nephritis, Macrophages, Male, Mice, Inbred C57BL, Mice, Inbred NZB, T-Lymphocytes, Case-Control Studies, Cytokines, Mice, Knockout, Chemokines, Mice, Inbred MRL lpr, Toll-Like Receptor 2, Toll-Like Receptor 4, Mice, Chemokine CXCL13, Young Adult, Biglycan
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.